Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX December health sector winners… and a 91pc drop for a trial-flopped stock
News
ASX December Winners: Santa didn’t rally but at least these 50 stocks went okay
Health & Biotech
Health Check: Percheron board addresses shareholders after failed phase 2b trial
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Scott Power: Which stock fell off its perch on poor trial results this week?
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
News
ASX Lunch Wrap: ASX higher ahead of Fed; MinRes completes $780m gas deal with Rinehart
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Health Check: Clinical trials don’t sleigh down for the silly season
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Scott Power: Which small medtech lifted 70pc this week after US contract win?
Health & Biotech
Health Check: No sign of frayed nerves as Orthocell girds for US approval
Health & Biotech
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
Health & Biotech
Five ASX healthcare companies poised for game-changing catalysts
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Dr Boreham’s Crucible: Does this biotech have the horsepower to become ‘the next Neuren’?
Health & Biotech
